AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-141745019/provectus-receives-fourth-pharmaceutical.html" title="Facts and information about Provectus receives fourth pharmaceutical patent for anti-cancer agents.">Provectus receives fourth pharmaceutical patent for anti-cancer agents.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Provectus receives fourth pharmaceutical patent for anti-cancer agents.
(From Chemical Business NewsBase - Press Release)
Provectus Pharmaceuticals Inc (Provectus) has received the company's fourteenth US patent (US Patent 6,991,776), which is its fourth US patent for its pharmaceutical products. The patent covers use of the company's anti-cancer pharmaceutical agent PV-10 for radiosensitization, augmenting coverage provided by the company's earlier patents for cancer treatment and …
Related articles from newspapers, magazines, journals, and more
-
- Synta Pharmaceuticals announces Phase II trial data showing STA-4783 doubles...
-
News wire article from: Chemical Business Newsbase
September 11, 2006
700+ words
-
- Medarex announces positive data with MDX-010 and dacarbazine combination in...
-
News wire article from: Asia Africa Intelligence Wire
June 7, 2004
700+ words
-
- Pain Therapeutics announces new clinical opportunity in metastatic melanoma.
-
News wire article from: Chemical Business Newsbase
November 8, 2006
700+ words
-
- Preliminary analysis of Phase II study shows 53% of patients with stage IV...
-
News wire article from: Asia Africa Intelligence Wire
May 14, 2005
700+ words
-
- Vical initiates pivotal Phase III trial of Allovectin-7 as first-line therapy...
-
News wire article from: Chemical Business Newsbase
January 4, 2007
700+ words
